NCT00463580 2025-07-08
Infliximab
Emory University
Phase 4 Completed
Clinical Trials
10 trialsNCT02711202 2025-06-04
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Phase NA Completed
NCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT02136069 2021-12-03
GARDENIA
Hoffmann-La Roche
Phase 3 Completed
NCT00040885 2016-12-07
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT00004941 2015-03-25
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
FDA Office of Orphan Products Development
Phase 3 Completed
NCT00060502 2011-05-17
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
Centocor, Inc.
Phase 2 Completed
NCT00228839 2009-06-30
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease
Emory University
Phase 1 Completed
NCT00432406 2009-03-11
Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
Chinese University of Hong Kong
Phase 4 Completed